Hospitalization Rates in Patients with Heart Failure and Reduced Ejection Fraction Initiating Sacubitril/Valsartan or Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers: A Retrospective Cohort Study-Reference-Cited by-同舟云学术

Hospitalization Rates in Patients with Heart Failure and Reduced Ejection Fraction Initiating Sacubitril/Valsartan or Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers: A Retrospective Cohort Study

Published:2022-01-29 Issue:1 Volume:11 Page:113-127
ISSN:2193-8261
Container-title:Cardiology and Therapy
language:en
Short-container-title:Cardiol Ther

Author:

Houchen Emma,Loefroth Emil,Schlienger Raymond,Proudfoot Clare,Corda Stefano,Saha Sibasish,Satwase Sarvesh K.,Studer Rachel

Funder

Novartis

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40119-021-00252-4.pdf

Reference24 articles.

1. Virani SS, Alonso A, Aparicio HJ, et al. Heart disease and stroke statistics-2021 update: a report from the American Heart Association. Circulation. 2021;143(8):e254–743.

2. Lippi G, Sanchis-Gomar F. Global epidemiology and future trends of heart failure. AME Med J. 2020;5:15.

3. Seferovic PM, Ponikowski P, Anker SD, et al. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21(10):1169–86.

4. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Cardiac Fail. 2017;23(8):628–51.

5. Fala L. Entresto (sacubitril/valsartan): first-in-class angiotensin receptor neprilysin inhibitor FDA approved for patients with heart failure. Am Health Drug Benefits. 2015;8(6):330–4.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of sacubitril/valsartan on hospital readmissions in heart failure with reduced ejection fraction in Saudi Arabia: A multicenter retrospective cohort study;Medicine;2024-07-26

2. Icariin improves cardiac function and remodeling via the TGF-β1/Smad signaling pathway in rats following myocardial infarction;European Journal of Medical Research;2023-12-19

3. Sacubitril/Valsartan in Heart Failure with Hypertension Patients: Real-World Experiences on Different Ages, Drug Doses, and Renal Functions;High Blood Pressure & Cardiovascular Prevention;2023-11-18

4. Sacubitril/Valsartan in the primary treatment of heart failure with reduced ejection fraction (HFrEF);Die Kardiologie;2023-10-20

5. Angiotensin-Converting Enzyme and Heart Failure;Frontiers in Bioscience-Landmark;2023-07-26